Challenger (ASX:CGF): Are investors panicking too much?
Shareholders in Challenger (ASX:CGF) didn’t take the news of Apollo’s sell down well. Apollo, a global fund manager, sold half…
Is the September Effect Real? Here’s What the Historical Data says and The Challenge Facing Investors
One of the perceived market phenomena is the “September Effect,” observed when the monthly returns during the month of September…
IPhone 16 Launch Event: Should You Buy Apple Stock Now
The highly awaited event of Apple witnessed the launch of the iPhone 16 series on September 9, 2024. It launches…
Invion (ASX:IVX): Using Photodynamic Therapy to fight cancer
Unless you’re a professional dermatologist, you may not have ever heard of Photodynamic Therapy, let alone thought of it as…
Bio Gene Technology (ASX:BGT): Commercialising a new class of insecticides
Bio Gene Technology (ASX:BGT) ASX-listed AgTech company developing two compounds – Flavocide™ and Qcide™ – as insecticides. Investors may hear…
Paradigm Biopharmaceuticals (ASX:PAR): An osteoarthritis solution that could hit the market within 3 years
If you thought the were plenty of treatments for osteoarthritis already, Paradigm Biopharmaceuticals (ASX:PAR) is a company that has something…
Cann Group (ASX:CAN): Successfully producing GMP medicinal cannabis since 2017
Cann Group (ASX:CAN) is the first company in Australia that was issued a medicinal cannabis license, granted by the Australian…
CET1 ratio: If you invest in ASX bank stocks, here’s why it is an important metric to know
In this article we look at the Common Equity Tier 1 (CET1) ratio – what it is and why it…
Star Entertainment Group (ASX:SGR): Where to now in a post-COVID world? Can it avoid a looming cash crunch?
In a July interview with the AFR, Star Entertainment Group boss Steve McCann admitted that his company’s pre-pandemic glory days…
Prescient Therapeutics (ASX:PTX): About to take the plunge into a Phase 2 trial against T-Cell Lymphoma
There’s plenty of ASX oncology biotechs conducting clinical trials, but Prescient Therapeutics (ASX:PTX) is one of the closest to commercialisation.…
5 crucial things to look for in the annual report of an ASX company that may give you an advantage over other investors
5 crucial things to look out for in the annual report of an ASX company! The ASX reporting season is…
Humm Group (ASX:HUM): Its no Big 4 Bank, but has defied the market in 2024
Humm Group (ASX:HUM) has not had the year you might expect to a financier that is not either a Big…
Here are 5 ASX stocks at 12 month highs, and whether it is time to buy
Here are 5 ASX stocks at 12 month highs! Humm Group (ASX:HUM) Humm has been through a difficult few…
Percheron Therapeutics (ASX:PER): Releasing Phase II data by the end of CY24, and successful data could lead to a major re-rate
It has been less then a year since Antisense Therapeutics changed its name to Percheron Therapeutics (ASX:PER). It is common…
Underlying v Statutory results? There’s a big difference between the 2 – here’s how to tell
When companies report results, you’ll hear underlying and statutory results. What is the difference between the two and how big…